**Supplemental Table 1. Exclusion criteria**

|  |  |
| --- | --- |
| (1) | Severe diabetes mellitus |
|  | -Fasting blood glucose: ≥200 mg/dL |
| (2) | Abnormal electrolyte metabolism |
|  | -Na: <125 mEq/L or ≥155 mEq/L  |
|  | -K: <3.1 mEq/L or ≥5.5 mEq/L  |
|  | -Ca: <8.0 mg/dL or ≥12.1 mg/dL  |
| (3) | Liver enzymes |
|  | -AST: ≥2.5×ULN\* |
|  | -ALT: ≥2.5×ULN\* |
| (4) | Bile duct obstruction |
|  | -ALP: ≥2.5×ULN\* |
|  | -T-BIL: ≥3.0 mg/dL |
| (5) | Nephropathy |
|  | -CRE: ≥2 mg/dL |
|  | -BUN: ≥25 mg/dL |
| (6) | Abnormal amino acid metabolism |
| (7) | Hemophilia |
| (8) | Hypersensitivity to ingredients of the test solutions or control solutions |
| (9) | Hypoparathyroidism or hypothyroidism |
| (10) | Inflammatory bowel disease |
| (11) | Pregnant or breastfeeding |
| (12) | Underwent blood sampling or provided blood donation of more than 200 mL within 4 weeks before the informed consent.Underwent blood sampling or provided blood donation of more than 400 mL, within 12 weeks (male) or 16 weeks (female) before the day of informed consent |
| (13) | Participated in a clinical trial or clinical study and received a drug within 16 weeks before the day of informed consent |
| (14) | Deemed unsuitable for inclusion in the study for any other reason based on assessment by the investigator or sub-investigator |

\* ULN: Upper Limit of Normal

AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; T-BIL, total bilirubin; CRE, creatinine; BUN, blood urea nitrogen.

**Supplemental table 2. Actual volumes of the Test and Control solutions administered**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | POD1 | POD2 | POD3 | POD4 | POD5 | POD6 | POD7 |
| Test solutions |  |  |  |  |  |  |  |
|  | OPF-108-1 | 34.57±6.43(34) | 35.73±6.70(47) | 38.60±7.27(19) | - | - | - | - |
|  | OPF-108-2 | - | - | 34.10±5.26(27) | 36.00±6.51(46) | 36.00±6.51(46) | 34.18±8.37(45) | 31.35±7.14(43) |
| Control solutions |  |  |  |  |  |  |  |
|  | ELN-1 | 36.21±8.03(40) | 36.53±6.89(55) | 37.35±7.60(27) | - | - | - | - |
|  | ELN-2 | - | - | 35.73±6.16(28) | 36.42±7.11(54) | 36.39±7.02(54) | 35.88±7.80(54) | 30.92±6.80(54) |

Data are means ± SD, mL/kg body weight (n)

**Supplemental table 3. Actual calories of the Test and Control solutions administered**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | POD1 | POD2 | POD3 | POD4 | POD5 | POD6 | POD7 |
| Test solutions |  |  |  |  |  |  |  |
|  | OPF-108-1 | 19.36±3.60(34) | 20.01±3.75(47) | 21.62±4.07 (19) | - | - | - | - |
|  | OPF-108-2 | - | - | 27.96±4.32(27) | 29.52±5.34(46) | 29.52±5.34(46) | 28.03±6.87(45) | 25.71±5.86(43) |
| Control solutions |  |  |  |  |  |  |  |
|  | ELN-1 | 20.28±4.50(40) | 20.46±3.86(55) | 20.92±4.25(27) | - | - | - | - |
|  | ELN-2 | - | - | 29.30±5.05(28) | 29.86±5.83(54) | 29.84±5.75(54) | 29.42±6.40(54) | 25.35±5.58(54) |

Data are means ± SD, kcal/kg body weight (n)

**Supplemental table 4. Actual amino acid amounts of the Test and Control solutions administered**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | POD1 | POD2 | POD3 | POD4 | POD5 | POD6 | POD7 |
| Test solutions |  |  |  |  |  |  |  |
|  | OPF-108-1 | 0.69±0.13(34) | 0.71±0.13(47) | 0.77±0.15 (19) | - | - | - | - |
|  | OPF-108-2 | - | - | 1.02±0.16(27) | 1.08±0.20(46) | 1.08±0.20(46) | 1.03±0.25(45) | 0.94±0.21(43) |
| Control solutions |  |  |  |  |  |  |  |
|  | ELN-1 | 0.72±0.16(40) | 0.73±0.14 (55) | 0.75±0.15(27) | - | - | - | - |
|  | ELN-2 | - | - | 1.07±0.18(28) | 1.09±0.21(54) | 1.09±0.21(54) | 1.08±0.23(54) | 0.93±0.20(54) |

Data are means ± SD, g/kg body weight (n)